Sean A. McCarthy - 09 May 2022 Form 4 Insider Report for CytomX Therapeutics, Inc. (CTMX)

Role
President and CEO, Director
Signature
/s/ Lloyd Rowland, as Attorney-in-Fact for Sean A. McCarthy
Issuer symbol
CTMX
Transactions as of
09 May 2022
Net transactions value
+$85,930
Form type
4
Filing time
11 May 2022, 16:51:34 UTC
Previous filing
04 Feb 2022
Next filing
21 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CTMX Common Stock Options Exercise $63,071 +66,742 +38% $0.9450 241,664 09 May 2022 Direct F1
transaction CTMX Common Stock Options Exercise $22,859 +24,189 +10% $0.9450 265,853 09 May 2022 Direct F1
holding CTMX Common Stock 93,158 09 May 2022 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTMX Stock Option (Right to Buy) Options Exercise $0 -66,742 -100% $0.000000* 0 09 May 2022 Common Stock 66,742 $0.9450 Direct F3
transaction CTMX Stock Option (Right to Buy) Options Exercise $0 -24,189 -100% $0.000000* 0 09 May 2022 Common Stock 24,189 $0.9450 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 75,000 restricted stock units.
F2 Shares held by Sean A. McCarthy 2018 Trust, of which Reporting Person is trustee.
F3 100% of the shares subject to the option are fully vested and exercisable.